← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Nuvox Pharma, Llc
Tucson, AZ
$10,203,681
Total funding
14
Grants
Funding over time
peak $1.3M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,203,681 · 14
By mechanism
R44$6,586,961 · 4
R41$1,825,077 · 5
U44$900,552 · 1
R43$666,091 · 3
N43$225,000 · 1
Investigators at Nuvox Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$1,033,173
R44 · FY2019 · CA
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2022 · CA
Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma$1,000,000
R44 · FY2014 · CA
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2017 · CA
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$963,578
R44 · FY2018 · CA
Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic$919,366
R44 · FY2025 · CA
Targeted Blood Brain Barrier Permeability Changes with Ultrasound & Microbubbles$507,257
R41 · FY2008 · NS
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$492,571
R44 · FY2023 · CA
NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice$478,050
R41 · FY2021 · NS
Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management$317,743
R43 · FY2017 · HL
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$301,366
U44 · FY2023 · NS
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$299,943
U44 · FY2025 · NS
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$299,243
U44 · FY2024 · NS
B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer$298,820
R41 · FY2016 · CA
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$297,786
R41 · FY2016 · CA
Targeted and Non-targeted Microbubbles for Pediatric Applications$243,164
R41 · FY2016 · HD
IGF::OT::IGF SBIR TOPIC 85 TO SUPPORT THE DEVELOPMENT OF TARGET SPECIFIC MOLECULAR IMAGING AGENTS IN COMBINATION WITH EXISTING IMAGING MODALITIES TO DETECT HIGH RISK ATHEROSCLEROTIC PLAQUE.$225,000
N43 · FY2014 · HL
Development of Novel Sensitizer to Improve Response of Hypoxic Tumors to Radiatio$204,360
R43 · FY2010 · CA
Sonothrombolysis of Vascular Clots with Targeted Bubbles$178,273
R44 · FY2007 · HL
Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting$143,988
R43 · FY2018 · NS